Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Rapper Fat Joe recently shared how he’s been using the Type 2 diabetes medication Ozempic to maintain his 200-pound weight ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...